AusBiotech July journal features 'manufacturing, money and medtech'
08 July, 2014The latest edition of AusBiotech's journal, Australasian Biotechnology (July 2014, Volume 24, Number 2), is out now.
NeuClone signs biosimilar deal with Serum Institute
07 July, 2014 by Dylan Bushell-EmblingSydney's NeuClone has entered a global partnership with The Serum Institute of India to produce a portfolio of 10 biosimilar monoclonal antibody drugs.
Analytica recruits clinicians for PeriCoach rollout
03 July, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) has recruited the first group of Australian clinician referral partners for its controlled launch of urinary incontinence device therapy PeriCoach.
Support for small to medium businesses
03 July, 2014The Entrepreneurs' Infrastructure Programme is accepting applications for Business Evaluations and Business Growth Grants.
AusBiotech wins grant to develop Australian medtech directory for China
03 July, 2014AusBiotech has been awarded a grant to develop a bilingual directory of Australian medical technology (devices and diagnostics) companies in Chinese/English to support business partnering and facilitate trade with China.
Simavita doubles Aust sales, books first US revenues
03 July, 2014 by Dylan Bushell-EmblingSimavita (ASX:SVA) revealed it had doubled Australian monthly revenues for its incontinence management products and its distribution partner has commenced sales in the US.
GI Dynamics warns on Q2 revenue
02 July, 2014 by Dylan Bushell-EmblingGI Dynamics (ASX:GID) has estimated it will report a slight sequential decline in Q2 revenue, and announced the resignation of chief commercial officer Mark C Twyman.
Australia ranks fourth on biotech scorecard
01 July, 2014 by Lauren DavisScientific American Worldview has released its latest scorecard, which measures biotechnology innovation around the world. Australia ranked extremely well on the scorecard, jumping from seventh position last year to fourth this year.
Iluvien close to approval in 10 more EU markets
01 July, 2014 by Dylan Bushell-EmblingpSivida (ASX:PVA) partner Alimera is on track to securing approval for diabetic macular oedema treatment Iluvien in 10 more European markets, taking the total up to 17.
Australian Export Awards 2014 now open
01 July, 2014The Australian Export Awards, run by Austrade and the Australia Chamber of Commerce and Industry, has launched its 2014 program and is looking for Australia's business success stories.
Pharmaxis short-listed for Prix Galien UK award
30 June, 2014 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) and seven multinational biotechs with a presence in Australia have been short-listed for the Prix Galien UK pharmaceutical R&D awards.
Anatara seeking partners as LSQ finds one
27 June, 2014 by Dylan Bushell-EmblingAnatara Lifesciences used BIO 2014 to seek partners for a non-antibiotic diarrhoea treatment, while Life Sciences Queensland has signed an MoU with biotech accelerator Bioindustrial Innovation Canada.
Admedus expects $9m in income for FY13-14
27 June, 2014 by Dylan Bushell-EmblingAdmedus (ASX:AHZ) made good progress with the commercialisation of CardioCel during the financial year and hopes to report the results of its subsidiary's HSV-2 trial next quarter.
Entrepreneurs' Infrastructure Programme seeks comment
26 June, 2014AusBiotech has made preliminary comment regarding the establishment of the Entrepreneurs' Infrastructure Programme (EIP), based on questions posed in the EIP Discussion Paper (June 2014).
pSivida licensee gets Italian approval for Iluvien
25 June, 2014pSivida (ASX:PVA) has revealed its licensee Alimera Sciences has secured Class C approval in Italy for diabetic macular oedema treatment Iluvien.
